Starpharma Holdings Ltd has released a press release.
Appendix 4C - Quarterly Cashflow Reoprt
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Starpharmas DEP eliminates cabazitaxel neutropenia
- VivaGel active against Zika virus
- DEP cabazitaxel shows complete, sustained tumour regression
- Starpharma signs drug delivery license with AstraZeneca
- Successful completion of VivaGel study sexually active women
Later from Starpharma
- Starpharma signs license for a VivaGel condom in China
- New DEP drug delivery program initiated with AstraZeneca
- VivaGel condom receives regulatory approval in Canada
- Enrolment complete for Phase 3 VivaGel BV-R program
- Additional Priostar Glyphosate Patent Allowed in US
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma